GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Retained Earnings

Circio Holding ASA (OSL:CRNA) Retained Earnings : kr-140.25 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Circio Holding ASA's retained earnings for the quarter that ended in Dec. 2023 was kr-140.25 Mil.

Circio Holding ASA's quarterly retained earnings declined from Dec. 2022 (kr-123.67 Mil) to Jun. 2023 (kr-199.63 Mil) but then increased from Jun. 2023 (kr-199.63 Mil) to Dec. 2023 (kr-140.25 Mil).

Circio Holding ASA's annual retained earnings declined from Dec. 2021 (kr309.29 Mil) to Dec. 2022 (kr-123.67 Mil) and declined from Dec. 2022 (kr-123.67 Mil) to Dec. 2023 (kr-140.25 Mil).


Circio Holding ASA Retained Earnings Historical Data

The historical data trend for Circio Holding ASA's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Retained Earnings Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -670.01 -778.14 309.29 -123.67 -140.25

Circio Holding ASA Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 249.69 228.96 -123.67 -199.63 -140.25

Circio Holding ASA Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Circio Holding ASA  (OSL:CRNA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines